C

Calvary North Adelaide Hospital | Oncology Clinical Trials

Research site

(Unclaimed)

Location

89 Strangways Terrace, North Adelaide, South Australia, Australia

Site insights

Top conditions

Top treatments

Docetaxel

Radium-223 Dichloride

AGEN2034

Rindopepimut

INCB050465

Xofigo

GM-CSF

CPI-0610

Paclitaxel

Pelabresib

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 8 total trials

Investigation of Radium-223 Dichloride (Xofigo), a Treatment That Gives Off Radiation That Helps Kill Cancer Cells, Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy, NAH) in Patients With Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH

Researchers in this study want to compare how well drug radium-223 dichloride (Xofigo) and new (novel) anti-hormonal (NAH) therapy work in participan...

Active, not recruiting

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Drug: NAH therapy

Drug: Radium-223 dichloride (Xofigo, BAY88-8223)

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

A Phase 3, randomized, blinded study comparing pelabresib (CPI-0610) and ruxolitinib with placebo and ruxolitinib in myelofibrosis (MF) patients that...

Active, not recruiting

Myelofibrosis

Post-essential Thrombocythemia Myelofibrosis

Drug: Placebo

Drug: Pelabresib

Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy (PYRAMID-1)

This is a randomized, positive-controlled, open-label, international multicenter, Phase 3 clinical study to compare the efficacy and safety of pyroti...

Active, not recruiting

HER2 Exon 20 Mutation

Non-squamous NSCLC

Drug: Pyrotinib

Drug: Docetaxel

Study of BGB-A425 and LBL-007 in Combination with Tislelizumab in Advanced Solid Tumors

This is an open-label, multicenter, nonrandomized Phase 1 and 2 clinical trial evaluating various combinations of BGB-A425 and/or LBL-007 with tislel...

Enrolling

Locally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2

Drug: Tislelizumab

Drug: LBL-007